Transcatheter Arterial Embolization with Bleomycin-Lipiodol of Hepatic Hemangiomas: Safety, Efficacy and Predictors of Response
- 20 March 2024
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (7) , 931-942
Abstract
Purpose To evaluate the safety, efficacy and predictors of response of transcatheter arterial embolization (TAE) to treat hepatic hemangiomas (HHs). Materials and Methods A retrospective analysis was conducted of consecutive HH patients who received TAE with bleomycin-Lipiodol emulsion and gelatin sponge particles at three institutions from January 2014 to January 2021. TAE effectiveness was defined as more than 50% reduction of tumor volume. The effectiveness, safety, and CT changes of hemangiomas after TAE were assessed. Factors affecting TAE efficacy on tumor size were analyzed with logistic regression analysis. Results A total of 102 patients with 109 HHs were included. After treatment, both the tumor diameter and volume were significantly reduced from 8.5 ± 3.9 to 5.9 ± 3.8 cm (P < 0.001) and 412.6 ± 742.3 cm3 to 102.0 ± 232.7 cm3 (P < 0.001), respectively. TAE effectiveness was achieved in 80.7% (88/109) of hemangiomas, which was characterized by progressive reduction in tumor volume over time with Lipiodol retention. Atypical enhancement pattern (tiny enhancing dots in the hepatic arterial and portal venous phase) (p = 0.001) and central arterioportal shunt (APS) (p = 0.002) associated with the tumor were independent predictors of TAE ineffectiveness. Postembolization syndrome and transient increase in liver enzymes were common without severe complications and death. Conclusion TAE was safe and effective in reducing HH size. Lesion enhancement pattern and APS type were associated with TAE efficacy on tumor shrinkage. Level of Evidence Level 3, non-controlled retrospective cohort study. Graphical AbstractKeywords
Funding Information
- Key Scientific and Technological Projects of Changjiang Navigation Administration (202210005)
This publication has 19 references indexed in Scilit:
- Effectiveness of Transarterial Embolization in Treatment of Symptomatic Hepatic Hemangiomas: Systematic Review and Meta-analysisCardioVascular and Interventional Radiology, 2020
- Hepatic hemangioma with arterioportal shunt: Prevalence and lesion characteristics based on DSA, CT and MR imagingEuropean Journal of Radiology, 2019
- Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic HaemangiomaCardioVascular and Interventional Radiology, 2019
- Transarterial Bleomycin–Lipiodol Embolization (B/LE) for Symptomatic Giant Hepatic HemangiomaCardioVascular and Interventional Radiology, 2018
- Superselective Transarterial Chemoembolization as an Alternative to Surgery in Symptomatic/Enlarging Liver HemangiomasWorld Journal of Surgery, 2017
- EASL Clinical Practice Guidelines on the management of benign liver tumoursJournal of Hepatology, 2016
- Assessing Normal Growth of Hepatic Hemangiomas During Long-term Follow-upJAMA Surgery, 2014
- Minimally Invasive Treatment of Giant Haemangiomas of the Liver: Embolisation With BleomycinCardioVascular and Interventional Radiology, 2013
- Liver haemangioma: common and uncommon findings and how to improve the differential diagnosisEuropean Radiology, 2007
- Chemoembolization for Hepatocellular Carcinoma: Where Does the Truth Lie?Journal of Vascular and Interventional Radiology, 2002